A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53
Guardado en:
Autores principales: | Congcong Cao, Lin Yao, Aolin Li, Quan Zhang, Zhenan Zhang, Xiaofei Wang, Ying Gan, Yuchen Liu, Qian Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9664ba87b76a4ed9ba8fa2ebee558d7d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer
por: Aolin Li, et al.
Publicado: (2021) -
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
por: Yann Neuzillet, et al.
Publicado: (2012) -
TP53 in Myelodysplastic Syndromes
por: Yan Jiang, et al.
Publicado: (2021) -
Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
por: Elisabeth Silden, et al.
Publicado: (2013) -
CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
por: Rajeswari Jayavaradhan, et al.
Publicado: (2019)